Postoperatively, routine oxytocin administration to promote uterine contraction is advisable, thereby mitigating the need for secondary surgery resulting from rapid fibroid enlargement after delivery; for fibroids not temporarily suitable for concurrent management, a rigorous postoperative follow-up mechanism needs to be established, with regular imaging monitoring of fibroid size, location, and morphological changes. The gene discussed is OXT; the disease is leiomyoma.